Catalog No.
DVV00319
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV), Omicron, BA.4/5 strain, BA.5 strain, BA.4 strain
Host species
Human
Isotype
IgG1, lambda2
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD
Concentration
1.14 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2-2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY-CoV1404, LY3853113
Clone ID
Bebtelovimab
Dynamic Profiling and Prediction of Antibody Response to SARS-CoV-2 Booster-Inactivated Vaccines by Microsample-Driven Biosensor and Machine Learning. [DVV00319]
High Quality-Factor All–Dielectric Metacavity for Label–Free Biosensing. [DVV00319]
Comparative Effectiveness of Outpatient COVID-19 Therapies in Solid Organ Transplant Recipients., PMID:39791933
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis., PMID:39722466
Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19., PMID:39722116
SARS-CoV-2 variants and bebtelovimab: immune escape mechanisms revealed by computational studies., PMID:39618233
Impact of Bebtelovimab Treatment Timing on COVID-19 Outcomes in Ambulatory Solid Organ Transplant Recipients., PMID:39549258
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant., PMID:39543801
Investigating the Safety Profile of Fast-Track COVID-19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study., PMID:39533148
Adverse events associated with SARS-CoV-2 neutralizing monoclonal antibodies using the FDA adverse event reporting system database., PMID:39345748
Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis., PMID:39293594
Reprint of: Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic., PMID:39127938
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities., PMID:39126484
Bebtelovimab-bound SARS-CoV-2 RBD mutants: resistance profiling and validation with escape mutations, clinical results, and viral genome sequences., PMID:39107909
The safety signal detection and analysis of monoclonal antibodies against SARS-CoV-2 based on real-world evidence - the suitable selectivity for different populations., PMID:38639534
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies., PMID:38500835
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants., PMID:38399944
SARS-CoV-2 evolution during prolonged infection in immunocompromised patients., PMID:38364100
Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges., PMID:38334977
SARS-CoV-2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID-19 pandemic., PMID:38332930
Allosteric Signal within the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein Mediated by a Class 3 Monoclonal Antibody Revealed through Molecular Dynamics Simulations and Protein Residue Networks., PMID:38313482
Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID-19 infection at an ambulatory cancer center., PMID:38191852
Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic., PMID:38151202
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1., PMID:37896937
Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022-2023., PMID:37894075
A new multi-epitope vaccine candidate based on S and M proteins is effective in inducing humoral and cellular immune responses against SARS-CoV-2 variants: an in silico design approach., PMID:37874075
Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping., PMID:37828918
Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review., PMID:37719798
Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron., PMID:37708028
SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis., PMID:37701439
A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study., PMID:37680398
Anti-SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023., PMID:37651140
Effectiveness of Bebtelovimab Against Hospitalization and Death From the Omicron BA.4/BA.5 and BQ.1/BQ.1.1 Subvariants., PMID:37414096
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions., PMID:37318043
Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19., PMID:37313067
Digital PCR Discriminates between SARS-CoV-2 Omicron Variants and Immune Escape Mutations., PMID:37306573
SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes., PMID:37158832
Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review., PMID:37129306
Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era., PMID:37115780
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia., PMID:37085220
The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis., PMID:37085048
Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5., PMID:37072054
Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study., PMID:37011399
Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants., PMID:36992294
Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages., PMID:36968074
Insights on the interaction of SARS-CoV-2 variant B.1.617.2 with antibody CR3022 and analysis of antibody resistance., PMID:36940010
Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies., PMID:36925722
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies., PMID:36788246
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge., PMID:36768588
Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants., PMID:36756927
Bilateral Lung Transplantation With Donor Positive for COVID-19 Infection on Bronchoalveolar Lavage: A Case Report., PMID:36740511
For research use only. Not for human or drug use.
